2 weeks Ago By ABMN Staff
Forefront Analytics LLC raised its holdings in shares of Kronos Bio, Inc. ( NASDAQ:KRON – Free Report ) by 75.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC).
The fund owned 134,998 shares of the company’s stock after purchasing an additional 57,867 shares during the period. Forefront Analytics LLC owned about 0.22% of Kronos Bio worth $167,000 as of its most recent SEC filing.
Several other institutional investors have also recently added to or reduced their stakes in KRON. Acadian Asset Management LLC increased its stake in Kronos Bio by 58.8% during the second quarter.
Acadian Asset Management LLC now owns 1,229,910 shares of the company’s stock valued at $1,524,000 after purchasing an additional 455,351 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Kronos Bio by 14.
6% during the first quarter. Vanguard Group Inc. now owns 1,948,595 shares of the company’s stock worth $2,533,000 after acquiring an additional 247,918 shares during the last quarter.
Virtu Financial LLC bought a new position in shares of Kronos Bio during the first quarter worth about $71,000. Finally, Marquette Asset Management LLC grew its position in shares of Kronos Bio by 19.8% during the first quarter.
Marquette Asset Management LLC now owns 80,369 shares of the company’s stock worth $104,000 after acquiring an additional 13,269 shares during the last quarter. Institutional investors own 64.09% of the company’s stock.
Wall Street Analyst Weigh In Separately, HC Wainwright restated a “buy” rating and set a $2.25 price target on shares of Kronos Bio in a research report on Monday, August 19th. Kronos Bio Stock Performance Kronos Bio stock opened at $0.
98 on Friday. The company has a 50-day simple moving average of $1.06 and a 200-day simple moving average of $1.
07. The firm has a market capitalization of $58.89 million, a P/E ratio of -0.
49 and a beta of 1.87. Kronos Bio, Inc.
has a one year low of $0.69 and a one year high of $1.60.
Kronos Bio ( NASDAQ:KRON – Get Free Report ) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.
32) by $0.05. The business had revenue of $2.
69 million during the quarter, compared to analyst estimates of $1.75 million. Kronos Bio had a negative net margin of 1,222.
83% and a negative return on equity of 68.82%. As a group, sell-side analysts forecast that Kronos Bio, Inc.
will post -1.33 earnings per share for the current year. About Kronos Bio ( Free Report ) Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States.
Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. Featured Articles Want to see what other hedge funds are holding KRON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kronos Bio, Inc.
( NASDAQ:KRON – Free Report ). Receive News & Ratings for Kronos Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kronos Bio and related companies with MarketBeat.com's FREE daily email newsletter .
.
